Key result
Statins show experimental promise in pulmonary hypertension but lack definitive clinical evidence.
Why the study?
Does statin therapy improve outcomes in patients with pulmonary hypertension?
Does statin therapy improve outcomes in patients with pulmonary hypertension?
While experimental data suggest statins may benefit pulmonary hypertension by affecting remodeling and endothelial dysfunction, clinical evidence remains controversial and requires large randomized trials.
Answers are grounded in this paper and cite their sources.
Statin therapy should not be used for pulmonary hypertension on current evidence; leaves open whether experimental benefits will translate in large placebo-controlled trials.
The present publications' review considers perspectives of application of statins under pulmonary hypertension. Nowadays, there are quite encouraging experimental data concerning positive versatile effect of statins on lesser blood circulation. The results of study of this issue with participation of patients are singular and continue to be controversial still. The clinical substantiation of application of new pharmaceuticals effecting molecular mechanisms of pathogenesis of pulmonary hypertension (re-modeling, endothelial dysfunction, function of right ventricle) requires carrying out of large investigations placebo-controlled by design and statistical processing. Precisely in this context the application of statins is of interest as potentially strategic direction in treatment of pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Baksheev et al. (2016) conducted a review in Pulmonary hypertension. Statins was evaluated. Statins show encouraging experimental effects in pulmonary hypertension, but clinical data remain singular and controversial, necessitating large placebo-controlled trials.
Synapse has enriched 10 related papers. Consider them for comparative context: